DWAM
RLAY icon

Duncan Williams Asset Management’s Relay Therapeutics RLAY Stock Holding History

Duncan Williams Asset Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$260K Buy
13,876
+2,438
+21% +$35.4K 0.06% 145
2026
Q1 		$114K Sell
11,438
-325
-3% -$2.91K 0.03% 150
2025
Q4 		$99.9K Buy
+11,763
New +$83.9K 0.02% 166

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Duncan Williams Asset Management's RLAY Position: Q2 2026 in Review

Duncan Williams Asset Management increased its Relay Therapeutics (RLAY) stake by 21% in Q2 2026, buying an estimated $35.4K and bringing the position to 13,876 shares worth $260K. The position accounts for 0.06% of the portfolio, ranked #145.

Duncan Williams Asset Management first reported a position in RLAY in Q4 2025 and has held it in 3 quarters since. 260 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Duncan Williams Asset Management held 13,876 shares of Relay Therapeutics worth $260K as of Q2 2026.
  • Duncan Williams Asset Management bought 2,438 Relay Therapeutics shares in Q2 2026, an estimated $35.4K.
  • Relay Therapeutics made up 0.06% of Duncan Williams Asset Management's portfolio in Q2 2026, its #145 holding.
  • Duncan Williams Asset Management first reported a position in Relay Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 260 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Duncan Williams Asset Management's 13F filing for Q2 2026, filed 22 Jul 2026.